Skip to main content

Advertisement

Figure 3 | BMC Cancer

Figure 3

From: Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers

Figure 3

Chk1 inhibition by V158411 induces Chk1 degradation and H2AX phosphorylation. Triple-negative breast or ovarian cancer cells (A) or luminal breast cancer cell lines (B) were exposed to the indicated concentrations of V158411 for 24 hours. C. MDA-MB-468 TNBC cells were treated with 1 μM V158411 for 0 to 24 hours. Protein changes were assessed by immunoblotting.

Back to article page